Pages

.

Showing posts with label Development. Show all posts
Showing posts with label Development. Show all posts

Stephen Ritter Joins Emotient as Senior Vice President of Product Development

SAN DIEGO, June 19, 2014 /PRNewswire/ -- Emotient, the leading provider of facial expression analysis software, today announced that Stephen Ritter joined the company as Senior Vice President of Product Development. Stephen brings extensive engineering management experience from successful start-ups and larger enterprises, including Cypher Genomics, Websense and McAfee, an Intel company.

"Steve is a proven technology leader who has demonstrated success in transforming cutting edge technology into highly successful commercial products," said Ken Denman, President and CEO, Emotient. "We will rely on his expertise as we continue to drive our innovative, emotion-aware software into the healthcare and retail markets, through a cloud-based platform."

"Emotient is at the forefront of a massive trend in emotion-aware computing," said Ritter.  "Emotient's founding team is spearheading the development of proprietary technology that sets the industry standard for accuracy and real-time delivery of facial expression data and analysis. I look forward to leading the commercial delivery of new emotion analytics products for retail and healthcare based on our state-of-the-art technology."

Most recently, Stephen served as CTO at Cypher Genomics, a leading genome informatics company. Previously, he was Vice President, Engineering for Websense, where he led a global team in the development of the market leading web security product, TRITON Web Security Gateway. Prior to WebSense he served as senior director of engineering at McAfee, now an Intel company, where he developed one of the most advanced and scalable security management software systems in the industry.

Ritter began his career as an accomplished software developer/architect and currently holds six patents in the area of information security. He holds a B.S. in Cognitive Science from UC San Diego.

About Emotient – Emotion Recognition Technology (www.emotient.com)
Emotient, Inc., is the leading authority in facial expression analysis. Emotient's software translates facial expressions into actionable information, thereby enabling companies to develop emotion-aware technologies and to create new levels of customer engagement, research, and analysis. Emotient's facial expression technology is currently available to Global 2000 companies within the retail, healthcare and consumer packaged goods industries.

Emotient was founded by a team of six Ph.D.s from the University of California, San Diego, who are the foremost experts in applying machine learning, computer vision and cognitive neuroscience to facial behavioral analysis.

SOURCE Emotient

RELATED LINKS
http://www.emotient.com

reade more... Résuméabuiyad

NexID Receives Grants to Fund Further Development, Commercialization of Biometric 'Liveness Detection'

POTSDAM, N.Y., April 30, 2014 /PRNewswire/ -- NexID Biometrics LLC, whose "liveness detection" technology boosts protection in applications with critical security-authentication needs, today announced it has received a series of funding grants totaling $325,000, including a highly competitive award given to emerging companies in central New York state.

NexID, the first company to offer liveness detection software for fingerprint-sensors on mobile devices, said the grants will fund further research, development and commercialization of additional modes of authentication that go beyond its deep expertise in detecting and mitigating attempts to spoof fingerprint scanners used for authenticating entry to secure locations and systems.

NexID will participate with Clarkson University here and West Virginia University in the joint research into biometric security technology sponsored by the National Science Foundation and gain the right to license technology that results from that research. NexID is a venture "spinout" from both institutions, with several of the company's founders serving on their faculty.

To expand the NSF-funded work at Clarkson and WVU, NexID has received a matching grant of $100,000 from Seaway Private Equity Corporation (SPEC) to develop a commercial liveness-detection application for security systems that scan people's faces and the irises in human eyes.  SPEC provides early stage equity capital funding for companies in St. Lawrence County, N.Y., with significant growth potential.

NexID also received a $150,000 Grant for Growth from the Syracuse-based CenterState Corporation for Economic Opportunity (CEO), which will be augmented by another matching grant from SPEC in the amount of $75,000.  The CenterState CEO grant to NexID was one of only two organizations awarded from among scores of companies that applied for funding.

"We expect this funding to extend and accelerate our operations through the two to three years it may take before NexID begins to realize royalty revenue from the licensing of our technology in these new areas," said Dr. Stephanie Schuckers, Professor of Electrical and Computer Engineering at Clarkson University and CEO of NexID.

Privately held, NexID has operated organically since 2007 by licensing the use of its software to makers of traditional fingerprint-scanning systems to authenticate users at international border crossings and to gain access to laptops, systems and secure locations.  NexID's research into spoofing techniques and liveness detection software raises the effectiveness of fingerprint-scanning systems to over 95 percent.

The introduction of fingerprint scanning in popular smartphones, such as Apple's iPhone 5S with TouchID and Samsung's Galaxy S® 5, has caused the market for scanner-equipped mobile devices – and the need to safeguard them from spoofing -- to explode.  Meanwhile, heightened concerns for security around the world are driving global demand for additional modes of biometric authentication.

"We're proud of the renowned expertise in biometrics and cyber security that Dr. Schuckers and NexID bring to Clarkson," said University President Anthony Collins, Ph. D.  "It's an honor for our institution to be associated so closely with their leadership in this highly specialized area.

"Further, as a member of the Seaway Private Equity Corporation's Board of Directors, I'm pleased to see that NexID, truly a global center of excellence in biometrics technology here in the northern New York region, is receiving matching funds to further leverage this opportunity for growth," Collins said.

About NexID Biometrics
NexID Biometrics is a leading software and technology supplier to the biometric-authentication industry. The company develops and licenses liveness detection software that enables fingerprint-scanning technologies to more accurately, and with greater confidence, authenticate scanned images by mitigating spoof-related risks. The company also provides testing and analysis of fingerprint scanning devices to identify existing vulnerabilities to known spoofing strategies. The company's founders represent some of the world's leading authorities on biometric spoof mitigation and liveness detection.

Logo - http://photos.prnewswire.com/prnh/20131016/SF97206LOGO

SOURCE NexID

RELATED LINKS
http://www.nexidbiometrics.com

reade more... Résuméabuiyad

Patches of Cortical Layers Disrupted During Early Brain Development in Autism

SEATTLE, March 26, 2014 /PRNewswire/ --  Researchers at the University of California, San Diego School of Medicine and the Allen Institute for Brain Science have published a study that gives clear and direct new evidence that autism begins during pregnancy.

The study will be published in the March 26, 2014 online edition of the New England Journal of Medicine.  

The researchers – by Eric Courchesne, PhD, professor of neurosciences and director of the Autism Center of Excellence at UC San Diego, Ed S. Lein, PhD, of the Allen Institute for Brain Science in Seattle, and first author Rich Stoner, PhD, of the UC San Diego Autism Center of Excellence – analyzed 25 genes in post-mortem brain tissue of children with and without autism. These included genes that serve as biomarkers for brain cell types in different layers of the cortex, genes implicated in autism and several control genes.

"Building a baby's brain during pregnancy involves creating a cortex that contains six layers," Courchesne said. "We discovered focal patches of disrupted development of these cortical layers in the majority of children with autism." Stoner created the first three-dimensional model visualizing brain locations where patches of cortex had failed to develop the normal cell-layering pattern.

"The most surprising finding was the similar early developmental pathology across nearly all of the autistic brains, especially given the diversity of symptoms in patients with autism, as well as the extremely complex genetics behind the disorder," explained Lein.

During early brain development, each cortical layer develops its own specific types of brain cells, each with specific patterns of brain connectivity that perform unique and important roles in processing information. As a brain cell develops into a specific type in a specific layer with specific connections, it acquires a distinct genetic signature or "marker" that can be observed.

The study found that in the brains of children with autism key genetic markers were absent in brain cells in multiple layers. "This defect," Courchesne said, "indicates that the crucial early developmental step of creating six distinct layers with specific types of brain cells – something that begins in prenatal life – had been disrupted."

Equally important, said the scientists, these early developmental defects were present in focal patches of cortex, suggesting the defect is not uniform throughout the cortex. The brain regions most affected by focal patches of absent gene markers were the frontal and the temporal cortex, possibly illuminating why different functional systems are impacted across individuals with the disorder.

The frontal cortex is associated with higher-order brain function, such as complex communication and comprehension of social cues. The temporal cortex is associated with language. The disruptions of frontal and temporal cortical layers seen in the study may underlie symptoms most often displayed in autistic spectrum disorders. The visual cortex – an area of the brain associated with perception that tends to be spared in autism – displayed no abnormalities. 

"The fact that we were able to find these patches is remarkable, given that the cortex is roughly the size of the surface of a basketball, and we only examined pieces of tissue the size of a pencil eraser," said Lein. "This suggests that these abnormalities are quite pervasive across the surface of the cortex."

Researchers used data collected for the Allen Brain Atlas, as well as the BrainSpan Atlas of the Developing Human Brain, which was developed by a consortium of partners and funded by the National Institute of Mental Health. These rich resources allowed the scientific team to identify specific genes in the developing human brain that could be used as biomarkers for the different layer cell types.

Researching the origins of autism is challenging because it typically relies upon studying adult brains and attempting to extrapolate backwards. "In this case," Lein noted, "we were able to study autistic and control cases at a young age, giving us a unique insight into how autism presents in the developing brain."

"The finding that these defects occur in patches rather than across the entirety of cortex gives hope as well as insight about the nature of autism," added Courchesne.

According to the scientists, such patchy defects, as opposed to uniform cortical pathology, may help explain why many toddlers with autism show clinical improvement with early treatment and over time. The findings support the idea that in children with autism the brain can sometimes rewire connections to circumvent early focal defects, raising hope that understanding these patches may eventually open new avenues to explore how that improvement occurs.

Additional contributors to the study include Maggie L. Chow, PhD, and Subhojit Roy, MD, PhD, UC San Diego; Maureen P. Boyle, PhD, UC San Diego and Allen Institute; Peter R. Mouton, PhD, University of South Florida School of Medicine; Anthony Wynshaw-Boris, MD, PhD, Case Western Reserve University School of Medicine; and Sophia A. Colamarino, PhD, Stanford University School of Medicine. 

This research was supported by funds from the Simons Foundation, the Peter Emch Family Foundation, Cure Autism Now/Autism Speaks, the Thursday Club Juniors, the UC San Diego Autism Center of Excellence (NIMH grant P50-MH081755), and the Allen Institute for Brain Science (NIMH grant RC2MH089921).

The BrainSpan Atlas of the Developing Human Brain was supported by Award Numbers RC2MH089921 (PIs Ed Lein & Michael Hawrylycz, Allen Institute for Brain Science), RC2MH090047 (PI James A. Knowles, University of Southern California) and RC2MH089929 (PI Nenad Sestan, Yale University), totaling $16.2M, $8.9M and $9.9M, respectively, from the National Institute of Mental Health. This project is funded with 100% federal funds.  No non-government funds support the project.  The content is solely the responsibility of the respective authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health.

About the Allen Institute for Brain Science
The Allen Institute for Brain Science (www.alleninstitute.org) is an independent, 501(c)(3) nonprofit medical research organization dedicated to accelerating the understanding of how the human brain works in health and disease. Using a big science approach, the Allen Institute generates useful public resources used by researchers and organizations around the globe, drives technological and analytical advances, and discovers fundamental brain properties through integration of experiments, modeling and theory. Launched in 2003 with a seed contribution from founder and philanthropist Paul G. Allen, the Allen Institute is supported by a diversity of government, foundation and private funds to enable its projects. Given the Institute's achievements, Mr. Allen committed an additional $300 million in 2012 for the first four years of a ten-year plan to further propel and expand the Institute's scientific programs, bringing his total commitment to date to $500 million. The Allen Institute's data and tools are publicly available online at www.brain-map.org.

About UC San Diego Health Sciences
University of California, San Diego Health Sciences comprises clinical and academic entities – UC San Diego Health System, the region's only academic health system; UC San Diego School of Medicine, one of the nation's top research-intensive schools of medicine; and Skaggs School of Pharmacy and Pharmaceutical Sciences. The National Institutes of Health (NIH) ranks UC San Diego Health Sciences as one of the top two institutions in research funding per faculty member, and the School of Medicine is listed ninth in total NIH research funding. Part of the University of California system, UC San Diego – founded in 1960 – is renowned for collaborative and cross-disciplinary research that transcends traditional boundaries in science, engineering and the humanities.

Media Contacts:
Steven Cooper, Edelman for the Allen Institute for Brain Science
646.358.2765; Steven.Cooper@edelman.com

Scott LaFee, slafee@ucsd.edu 
619.543.6163

SOURCE Allen Institute for Brain Science

RELATED LINKS
http://www.alleninstitute.org

reade more... Résuméabuiyad

Dynasil's RMD Subsidiary Awarded $4 Million in Technology Development Grants by U.S. Department of Energy

WATERTOWN, Mass., Nov. 19, 2013 /PRNewswire/ -- Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received four grants totaling $4.0 million under the U.S. Department of Energy's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs.

"RMD's world-class research in nuclear detection continues to be on the cutting edge of new technologies," said Peter Sulick, Dynasil's Chairman of the Board, Chief Executive Officer and President. "Advanced nuclear detection materials are being developed for the Department of Energy to further replace helium-3 in the critical areas of homeland security and nuclear fuel accountability."

"From accounting for the country's nuclear fuel supply to monitoring the 15 million shipping containers that enter the U.S.'s ports every year for illicit nuclear materials, the new Phase II research projects RMD is undertaking through these SBIR/STTR Programs exemplify some of the world's most demanding security and safety needs," said Kanai Shah, Ph. D. President of Dynasil's RMD subsidiary. "Dynasil is proud to partner with the Department of Energy on these initiatives." 

"These Phase II grants capitalize on our technical and scientific capability in the development of scintillation materials and solid state sensors for nuclear detection," Kanai Shah said.  "Our work has significant application in the prevention of terrorist attacks and the safe guarding of nuclear materials, as well as in commercial endeavors such as energy exploration, nuclear power plant safety, medical imaging, basic science research and non-destructive testing."

About Dynasil
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets including medical imaging and sensors for non-destructive testing. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents.  The Company is based in Watertown, Massachusetts, with additional operations in MA, MN, NY, NJ and the United Kingdom. More information about the Company is available at www.dynasil.com.

Safe Harbor 
This news release may contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management.  These forward-looking statements may be identified by the use of words such as "plans", "intends," "may," "could," "expect," "estimate," "anticipate," "continue" or similar terms, though not all forward-looking statements contain such words.  The actual results of the future events described in such forward looking statements could differ materially from those stated in such forward looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to develop and commercialize our products, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in the Company's 2012 Annual Report on Form 10 K, as amended on February 14, 2013, including the risk factors contained in Item 1a, the Company's Quarterly Reports on Form 10-Q filed on February 13, 2013, May 15, 2013 and August 12, 2013 and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Patty Kehe
Corporate Secretary
Dynasil Corporation of America
Phone: (617) 668-6855
pkehe@dynasil.com

SOURCE Dynasil Corporation of America

RELATED LINKS
http://www.dynasil.com

reade more... Résuméabuiyad